Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
Journal of Clinical Oncology (2014)
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Susan Mary O'Brien, University of Texas MD Anderson Cancer Center
  • Peter Hillmen, St James's University Hospital
  • Richard R. Furman, Cornell University
  • Steven E. Coutre, Stanford University
  • Jeff Porter Sharman, Cancer Institute
  • Bruce D. Cheson, Georgetown University
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jacqueline Claudia Barrientos, Hofstra University
  • Andrew David Zelenetz, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, Ghent University
  • Ian Flinn, Sarah Cannon Research Institute
  • Herbert Aaron Eradat, University of California, Los Angeles
  • Nicole Lamanna, Columbia University
  • Michael J. Hallek, University of Cologne
  • Bertrand Coiffier, Claude Bernard University Lyon 1
  • Andrew Pettitt, University of Liverpool
  • Wei Ye
  • Thomas Michael Jahn, Children's Hospital Los Angeles
  • Lynne I. Wagner, Northwestern University
Link
Disciplines
Publication Date
May 20, 2014
Citation Information
Paolo Ghia, Susan Mary O'Brien, Peter Hillmen, Richard R. Furman, et al.. "Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results." Journal of Clinical Oncology Vol. 32 (2014) p. 7099
Available at: http://works.bepress.com/john-pagel/97/